FD274 is a potent dual PI3K/mTOR inhibitor with potential for research in acute myeloid leukemia (AML); it exhibits significant antiproliferative effects against AML cell lines (HL-60 and MOLM-16) and demonstrates dose-dependent tumor growth inhibition in an HL-60 xenograft model.